Literature DB >> 33968438

Systemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research.

Checca Bakkers1, Geert A A M Simkens1, Ignace H J T De Hingh1,2.   

Abstract

There is a lack of randomized or high-quality intention-to-treat cohort studies addressing the role of systemic therapy in addition to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as part of the treatment of colorectal peritoneal metastases (PM). Therefore, the choice whether or not to treat patients with systemic therapy is currently mainly based on expert opinion. As a result, treatment with neoadjuvant and/or adjuvant systemic therapy is implemented in various ways around the world. The aim of this review was to provide an overview of recent insights with regard to the systemic treatment of PM of colorectal origin obtained from clinical studies and translational research. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Systemic therapy; colorectal cancer; cytoreductive surgery (CRS); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal metastases (PM)

Year:  2021        PMID： 33968438      PMCID： PMC8100702          DOI： 10.21037/jgo-20-133

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  58 in total

Review 1.  EGFR antagonists in cancer treatment.

Authors:  Fortunato Ciardiello; Giampaolo Tortora
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

2.  Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis.

Authors:  Guillaume Passot; Delphine Vaudoyer; Eddy Cotte; Benoit You; Sylvie Isaac; François Noël Gilly; Faheez Mohamed; Olivier Glehen
Journal:  Ann Surg       Date:  2012-07       Impact factor: 12.969

3.  Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.

Authors:  Clarisse Eveno; Guillaume Passot; Diane Goéré; Philippe Soyer; Etienne Gayat; Olivier Glehen; Dominique Elias; Marc Pocard
Journal:  Ann Surg Oncol       Date:  2013-12-15       Impact factor: 5.344

4.  Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis.

Authors:  Geert A Simkens; Thijs R van Oudheusden; Misha D Luyer; Simon W Nienhuijs; Grard A Nieuwenhuijzen; Harm J Rutten; Ignace H de Hingh
Journal:  Ann Surg Oncol       Date:  2014-12-17       Impact factor: 5.344

5.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

6.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

Authors:  Dominique Elias; Jérémie H Lefevre; Julie Chevalier; Antoine Brouquet; Frédéric Marchal; Jean-Marc Classe; Gwenaël Ferron; Jean-Marc Guilloit; Pierre Meeus; Diane Goéré; Julia Bonastre
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

7.  Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  R A Devilee; G A Simkens; T R van Oudheusden; H J Rutten; G J Creemers; A J Ten Tije; I H de Hingh
Journal:  Ann Surg Oncol       Date:  2016-04-04       Impact factor: 5.344

8.  Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer.

Authors:  Y R B M van Gestel; I Thomassen; V E P P Lemmens; J F M Pruijt; M P P van Herk-Sukel; H J T Rutten; G J Creemers; I H J T de Hingh
Journal:  Eur J Surg Oncol       Date:  2013-10-16       Impact factor: 4.424

9.  Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.

Authors:  Wilhelm Graf; Peter H Cashin; Lana Ghanipour; Malin Enblad; Johan Botling; Alexei Terman; Helgi Birgisson
Journal:  Ann Surg Oncol       Date:  2019-09-30       Impact factor: 5.344

Review 10.  Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer.

Authors:  Geert A Simkens; Koen P Rovers; Simon W Nienhuijs; Ignace H de Hingh
Journal:  Cancer Manag Res       Date:  2017-06-30       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.